STUDI PENGGUNAAN ANTITUBERKULOSIS PADA PENDERITA MULTIDRUG-RESISTANT TUBERCULOSIS (Penelitian dilakukan di Poli TB MDR RSUD Dr. Soetomo Surabaya) by NATASYA OLGA REGINA, 051211132020
xi 
 
ABSTRACT 
 
DRUG UTILIZATION STUDY OF ANTI-TUBERCULOSIS IN  
PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS 
(Study at MDR-TB Unit at Dr. Soetomo Teaching Hospital Surabaya) 
 
Natasya Olga R.*, Wenny Putri*, Prastuti Asta**, Umi Fatmawati** 
*Department of Clinical Pharmacy, Airlangga University, Surabaya 
** Unit of MDR-TB Dr. Soetomo Hospital, Surabaya, Indonesia 
 
Backgrounds: Multidrug-Resistant Tuberculosis (MDR-TB) is tuberculosis 
which Mycobacterium tuberculosis develop resistance to Isoniazid and 
Rifampicin. The prevalence of MDR-TB in Indonesia is high since an 
estimated 6800 new cases report every year. Standard regimens are 
Pyrazinamide (Z)–Ethambutol (E)– Kanamycin (Km)–Levofloxacin (Lfx)–
Cycloserine (Cs)–Ethionamide (Eto) for intensive phase and Pyrazinamide 
(Z)–Ethambutol (E)–Levofloxacin (Lfx)–Cycloserine (Cs)–Ethionamide 
(Eto) for continuation phase. MDR-TB therapy is complicated and leads to 
many problems such as side effects, additional resistance, and non-adherence 
since patients are exposed to many drugs in the long term. Combination of 
anti-tuberculosis, dosing regimentation, and drug-related problems must be 
concern in order to achieve successful therapy.  
Objectives: The purposes of this study were to analyze the profiles of anti-
tuberculosis combination, dosing regimentation, and therapeutic outcomes, 
also identifying the problems related to anti-tuberculosis.  
Methods: It was a descriptive study using retrospective data of MDR-TB 
patients who completed the therapy from January 1st 2015 to December 31th 
2015, and conducted from March to May 2016 at Unit of MDR-TB in Dr. 
Soetomo Hospital Surabaya in Indonesia.  
Results: Based on the study of 40 medical records of MDR-TB patients that 
fulfilled the inclusion criteria, most patients received combination Z-E-Km-
Lfx-Cs-Eto (intensive phase) and Z-E-Lfx-Cs-Eto (continued phase). In the 
middle of therapy, there were some patients were changed to other 
combination and doses regimentation because of anti-tuberculosis side 
effects and additional resistance. The most prevalence of side effects such as 
hearing loss (60%) and increasing of uric acid. In this study, there were found 
patients which completed their therapy on normal duration (from 22 until 24 
months) and exceed normal duration (from 25 until 32 months). Almost all 
of patients (97%) completed MDR-TB therapy and cured. 
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